Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma

Figures & data

Table 1. Patient demographic and clinical characteristics.

Characteristic	No. of patients	%
Age
≤60	31	88.6
>60	4	11.4
Sex
Men	28	80.0
Women	7	20.0
ECOG performance status
0	13	37.2
1	18	51.4
2	4	11.4
Ann Arbor stage
IE	12	34.2
IIE	23	65.8
‘B’ symptom
Absent	24	68.6
Present	11	31.4
Serum LDH
Normal	22	62.9
Increased	13	37.1
NKIPI
0–1	22	62.9
2–3	13	37.1
Sites of paranasal extension
Paranasal sinuses	25	71.4
Nasopharynx	11	31.4
Tossil	3	8.6
Skull base	1	2.9
Oropharynx	7	20
Soft palate	9	25.7
Others	5	14.3
Perforation
Absent	27	77.1
Present	8	22.9
Locoregional LN invasion
Absent	10	28.6
Present	25	71.4
EBV DNA load
Low(<6.1 × 10^7 copies/ml)	25	71.4
High(>6.1 × 10^7 copies/ml)	10	28.6

Extensive IE: tumors extended beyond the nasal cavity and into the neighboring structures without any sign of nodal or distant dissemination.

Perforation: Tumor erosion normal tissue, forming a fistula between nasal cavity and the hard or soft palate.

Figure 1. Summary of treatment outcomes and treatment failures. CT indicates chemotherapy.

Figure 2. (a) OS and (b) PFS of patients.

Figure 3. Effect of complete response (CR) on (a) OS and (b) PFS of patients.

Figure 4. Effect of EBV load on (a) OS and (b) PFS of patients.

Figure 5. Effect of NKIPI score on (a) OS and (b) PFS of patients.

Figure 6. Effect of RT dose on (a) OS and (b) PFS of patients.

Table 2. Toxicity with the combined treatment.

Toxicity	Grade 1	Grade 2	Grade 3	Grade 4
Hematologic
Anemia	21	11	1	0
Leukocytopenia	3	17	11	2
Thrombocytopenia	6	19	5	0
Nonhematologic
Nausea/vomiting	13	2	0	0
Mucositis	7	17	9	2
Liver dysfunction,	15	2	0	0
Hyperbilirubinemia	8	0	0	0